The firm is the corporate venture capital arm of a global pharmaceutical company, operating through an evergreen investment structure with approximately €350M in capital. The firm focuses on early-stage biotechnology companies developing first-in-class, disease-modifying therapeutics and enabling technologies. The firm primarily invests at the Seed and Series A stages, frequently serving as a lead or co-lead investor alongside institutional syndicate partners. The firm also supports company formation and takes a long-term investment approach, structuring investments as equity financings without requiring commercial rights, licensing options, or acquisition rights. The firm invests globally, with activity across North America, Europe, and Asia.
The firm focuses on innovative therapeutics and enabling technologies across oncology, regenerative medicine, autoimmune diseases, infectious diseases, and digital technologies supporting pharmaceutical research and development. Areas of particular interest include immuno-oncology, targeted therapies, cell reprogramming, tissue regeneration, neurodegenerative diseases, and antimicrobial resistance. The firm also evaluates technologies that improve drug discovery, translational research, and clinical development. The firm primarily targets preclinical-stage assets and differentiated technology platforms capable of supporting multiple therapeutic programs, while remaining open to emerging approaches with significant potential to transform healthcare.
From a company and management team perspective, the firm invests in privately held biotechnology companies with proprietary technologies, strong scientific differentiation, and substantial long-term therapeutic potential. The firm generally favors technology platforms capable of generating multiple development programs rather than single-asset businesses. The firm frequently participates as an early institutional investor, seeks meaningful minority ownership positions, and typically requires a voting board seat. The firm actively supports portfolio companies through corporate strategy, scientific development, leadership recruitment, financing, and long-term company building.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
